Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and a Single Confirmatory Phase 3 Study of AR-301

ARDSDelisted Stock  USD 0.27  0.02  8.00%   
Slightly above 55% of Aridis Pharmaceuticals' private investors are presently thinking to get in. The analysis of overall sentiment of trading Aridis Pharmaceuticals pink sheet suggests that some investors are interested at this time. Aridis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Aridis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Aridis Pharmaceuticals pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Aridis daily returns and investor perception about the current price of Aridis Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
  
LOS GATOS, Calif., July 17, 2023 Aridis Pharmaceuticals, Inc. today announced positive feedback from the European Medicines Agency on the Companys proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus in mecha

Read at finance.yahoo.com
Yahoo News
  

Aridis Pharmaceuticals Fundamental Analysis

We analyze Aridis Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aridis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aridis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash And Equivalents

Cash And Equivalents Comparative Analysis

Aridis Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Aridis Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aridis Pharmaceuticals pink sheet to make a market-neutral strategy. Peer analysis of Aridis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Aridis Pharmaceuticals Related Equities

RVPHReviva Pharmaceuticals   8.77   
0%
100.0%
AKTXAkari Therapeutics   8.04   
0%
91.0%
ADTXAditxt   5.71   
0%
65.0%
ATXIAvenue Therapeutics   4.37   
0%
49.0%
ABVCABVC Biopharma   3.92   
0%
44.0%
RNAZTranscode Therapeutics   2.94   
0%
33.0%
DRMADermata Therapeutics   2.73   
0%
31.0%
KODKodiak Sciences   1.83   
0%
20.0%
UNCYUnicycive Therapeutics   1.47   
0%
16.0%
REVBRevelation Biosciences   1.33   
0%
15.0%
HOTHHoth Therapeutics   1.20   
0%
13.0%
NRBONeurobo Pharmaceuticals   0.43   
0%
4.0%
CGTXCognition Therapeutics   2.44   
27.0%
0%
ZVSAZyVersa Therapeutics   3.60   
41.0%
0%
RVPHWReviva Pharmaceuticals   4.35   
49.0%
0%
VRAXVirax Biolabs   4.83   
55.0%
0%
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Other Consideration for investing in Aridis Pink Sheet

If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios